News from mast therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 24, 2015, 19:30 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics Announces Management Change

Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced a management change in connection with...

Jan 07, 2015, 08:00 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics To Present At 2015 Biotech Showcase Conference On January 12th

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that the Company's Chief Executive...

Jan 05, 2015, 17:17 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics Provides Update On Epic Study Enrollment And 2015 Milestones

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today reported that enrollment in its pivotal EPIC study...

Dec 30, 2014, 08:00 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics To Host Corporate Conference Call

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that it will hold a conference call at...

Dec 09, 2014, 08:00 ET
Mast Therapeutics, Inc. logo

Mast Announces Plans For Development Of Vepoloxamer (MST-188) In Heart Failure

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today provided details of its plan to develop...

Nov 26, 2014, 08:00 ET
Mast Therapeutics, Inc. logo

Mast Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference On December 3rd

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that the Company's Chief Executive...

Nov 19, 2014, 08:00 ET
Mast Therapeutics, Inc. logo.

New Data From Nonclinical Heart Failure Study To Be Presented At American Heart Association Conference

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that data from MST-188 (vepoloxamer),...

Nov 17, 2014, 08:00 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics To Present MST-188 Data At 2014 American Society Of Hematology Conference

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that it will be presenting data from an...

Nov 13, 2014, 08:00 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics Announces Closing Of Underwritten Public Offering

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced...

Nov 06, 2014, 09:20 ET
Mast Therapeutics, Inc. logo

Mast Therapeutics Announces Pricing Of Underwritten Public Offering

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public...

Nov 05, 2014, 16:01 ET
Mast Therapeutics, Inc. logo

Mast Therapeutics Announces Underwritten Public Offering

Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that it intends to offer and sell equity...

Oct 31, 2014, 08:00 ET
Mast Therapeutics, Inc. logo.

Mast Therapeutics Reports Third Quarter 2014 Financial Results

Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today reported financial results for the quarter ended...

Oct 02, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics Announces Appointment Of Chief Medical Officer

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, announced today that Edwin L. Parsley, D.O. has joined...

Sep 08, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics Announces Positive Top Line Results From Phase 2 Study Of AIR001 For Pulmonary Arterial Hypertension And AIR001 Clinical Development Plan

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported top-line results from a Phase 2 study of AIR001 (sodium nitrite) inhalation solution...

Sep 02, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the...

Aug 29, 2014, 16:05 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics Announces Management Change

 Mast Therapeutics, Inc. (NYSE MKT: MSTX), an emerging biopharmaceutical company, announced today that Santosh Vetticaden, Chief Medical...

Aug 11, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics Provides Corporate Update And Reports Second Quarter 2014 Financial Results

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today provided a corporate update and reported financial results for the quarter ended June 30, 2014....

Aug 07, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics To Present At The Canaccord Genuity 34th Annual Growth Conference On August 14th

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the...

Jun 19, 2014, 16:15 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Announces Appointment Of Howard C. Dittrich M.D. To Board of Directors

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that Howard C. Dittrich, M.D., F.A.C.C., has joined its Board of Directors.  Dr....

Jun 16, 2014, 08:00 ET
Mast Therapeutics, Inc. logo. (PRNewsFoto/Mast Therapeutics, Inc.)

Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial

 Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in line with prior guidance, it has initiated patient enrollment in a sub-study...